Back to Search
Start Over
566 ENTPD1 as predictive marker of treatment response to gemogenovatucel-T (Vigil) in newly diagnosed ovarian cancer
- Source :
- Regular and Young Investigator Award Abstracts.
- Publication Year :
- 2022
- Publisher :
- BMJ Publishing Group Ltd, 2022.
Details
- Database :
- OpenAIRE
- Journal :
- Regular and Young Investigator Award Abstracts
- Accession number :
- edsair.doi...........727d10f89d4d5812b07637b3e113e061